Dorsal Root Ganglion Stimulation - 06/05/22
Doi : 10.1016/j.pmr.2022.02.005
Steven T. Potter, DO, MS a, ⁎ 
, Sean Welch, MD a, Faye Tata, DO a, Seth Probert, DO a, Ameet Nagpal, MD, MS, MEd b
, Sean Welch, MD a, Faye Tata, DO a, Seth Probert, DO a, Ameet Nagpal, MD, MS, MEd b a Department of Rehabilitation Medicine, UT Health San Antonio, Mail Code 7798, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA
b Department of Anesthesiology, UT Health San Antonio, Mail Code 7798, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA
∗Corresponding author.
Résumé |
The recent development and Food and Drug Administration approval in 2016 of dorsal root ganglion stimulation is a relatively new and novel form of target neuromodulation that promises improved outcomes compared with the current standard of care. Current literature is limited and dependent on industry evaluation. Future independent investigation will help clarify existing data and refine techniques to improve safety, effectiveness, and expand application.
Le texte complet de cet article est disponible en PDF.Keywords : Dorsal root ganglion stimulation, Neuromodulation, FDA approval
Plan
© 2022
Elsevier Inc. Tous droits réservés.
Vol 33 - N° 2
P. 359-378 - mai 2022 Retour au numéro
Article précédent
- Spinal Cord Stimulation : A Physiatric Perspective
- Mehul J. Desai, Ryan Aschenbrener, Eduardo J. Carrera, Nirguna Thalla
- Peripheral Nerve Stimulation for Chronic Pain and Migraine : A Review
- Samantha C. Erosa, Roya S. Moheimani, Jessica C. Oswald, Joel P. Castellanos, Mickey E. Abraham, Nathaniel M. Schuster
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?